#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...
pmlive.com/pharma_news/...
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE
The phase 3 study included around 2,600 patients
pmlive.com
September 23, 2025 at 8:23 AM